Get started
Author

Yayoi Fujioka

OpenAlex ID: A5103454927
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2020 · Hiroshi Sootome, Hidenori Fujita, et al. · Cancer Research · 215
PDF
The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2013 · Hidenori Fujita, Kazutaka Miyadera, et al. · Molecular Cancer Therapeutics · 38
Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
2020 · Hiroki Irie, Rumi Kawabata, et al. · Cancer Science · 36
PDF
Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.
2013 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Molecular Cancer Therapeutics · 28
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways
2019 · Hiromi Muraoka, Chihoko Yoshimura, et al. · Cancer Science · 27
PDF
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells
2016 · Hidenori Fujita, Akira Gomori, et al. · PLoS ONE · 21
PDF
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2019 · Hiroki Irie, Kimihiro Ito, et al. · Molecular Cancer Therapeutics · 15
Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .
2013 · Hiroshi Sootome, Yayoi Fujioka, et al. · Molecular Cancer Therapeutics · 11
Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.
2013 · Yoko Nakatsuru, Hiroaki Ochiiwa, et al. · Molecular Cancer Therapeutics · 2
Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile
2011 · Hidenori Fujita, Kazutaka Miyadera, et al. · Cancer Research · 2
Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis
2011 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Cancer Research · 2
Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al. · 1
Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 in vivo can be overcome by HER2 inhibition with TAS0728
2019 · Hiroki Irie, Rumi Kawabata, et al. · Molecular Cancer Therapeutics · 1
Abstract 1785: MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugs
2012 · Hidenori Fujita, Masanori Kato, et al. · Cancer Research · 1
Data from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
Data from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
Data from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Supplementary Figures 1 through 5 and Supplementary Tables 1 through 3 from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
PDF
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Figure S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Figure S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Figure S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Works count: 36
Citation count: 400
H-index: 8
I10-index: 8
Year
Topic
Type